Table 2.

Clinicopathological characteristics of patients by molecular risk.

		High risk (N = 37)		Low risk (N = 26)			All patients (N = 63)
		Value	%/IQR	Value	%/IQR	P‐value	Value	%/IQR
Male		21	57%	16	62%	0.704a	37	59%
Age	Median	64	57–70	68	60–72	0.718b	65	58–72
Primary tumour
Location (right sided)		4	11%	6	23%	0.190a	10	16%
Rectal cancer		21	57%	8	31%	0.042a	29	46%
T stage 3/4		30	81%	18	69%	0.277a	48	76%
Positive lymph node (pN+)		20	54%	11	42%	0.359a	31	49%
Adjuvant CTx		7	19%	7	27%	0.452a	14	22%
Neo‐adjuvant RTx		13	37%	3	12%	0.025a	16	26%
Liver metastases
CEA > 200		2	6%	0	0%	0.222a	2	3%
Synchronous	DFI < 12	12	32%	8	31%	0.889a	20	32%
Diameter > 5 (cm)		7	19%	2	8%	0.210a	9	14%
Number of mets > 1		7	19%	6	23%	0.688a	13	21%
Bilobar		5	14%	5	19%	0.541a	10	16%
R1 resection		5	14%	1	4%	0.198a	6	10%
Growth pattern 1	Replacement	27	73%	12	46%	0.106a	39	62%
	Desmoplastic	4	11%	6	23%		10	16%
	Pushing	1	3%	0	0%		1	2%
	Mixed	8	31%	5	14%		13	21%
Growth pattern 2	Replacement (any)	29	78%	21	81%	0.817a	50	79%
Differentiation	Good	4	11%	2	9%	0.975a	6	10%
	Moderate/good	5	14%	4	17%		9	15%
	Moderate	6	17%	5	22%		11	19%
	Poor/moderate	14	39%	8	35%		22	37%
	Poor	7	19%	4	17%		11	19%
Inflammation	Increased	5	14%	5	22%	0.513a	10	17%
	Moderate/increased	5	14%	6	26%		11	19%
	Moderate	11	31%	7	30%		18	31%
	Decreased/moderate	6	17%	2	9%		8	14%
	Decreased	9	25%	3	13%		12	20%

DFS = Disease Free Survival; pN+ = Pathological Node Positivity; CTx = Chemotherapy; RTx = Radiotherapy; CEA = Carcinoembryonic Antigen; R1 = Microscopic Irradical.

^aPearson X2.

^bMann–Whitney U test.